1. Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease
- Author
-
Janelidze, Shorena, Stomrud, Erik, Smith, Ruben, Palmqvist, Sebastian, Mattsson, Niklas, Airey, David C, Proctor, Nicholas K, Chai, Xiyun, Shcherbinin, Sergey, Sims, John R, Triana-Baltzer, Gallen, Theunis, Clara, Slemmon, Randy, Mercken, Marc, Kolb, Hartmuth, Dage, Jeffrey L, and Hansson, Oskar
- Subjects
Biochemistry and Cell Biology ,Biological Sciences ,Psychology ,Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD) ,Dementia ,Brain Disorders ,Biomedical Imaging ,Acquired Cognitive Impairment ,Neurodegenerative ,Clinical Research ,Alzheimer's Disease ,Aging ,Neurosciences ,Detection ,screening and diagnosis ,4.1 Discovery and preclinical testing of markers and technologies ,4.2 Evaluation of markers and technologies ,Neurological ,Aged ,Aged ,80 and over ,Alzheimer Disease ,Biomarkers ,Brain ,Carbolines ,Contrast Media ,Diagnosis ,Differential ,Feasibility Studies ,Female ,Humans ,Male ,Middle Aged ,Phosphorylation ,Positron-Emission Tomography ,Sweden ,tau Proteins ,Alzheimer's disease ,Tauopathy ,Small molecule ,Mouse model ,Immunohistochemistry ,Seeding ,Neurofibrillary Tangles ,Animals ,Mice ,Transgenic ,Mice ,Disease Models ,Animal ,Amyloid beta-Peptides ,Alzheimer’s disease ,Medical and Health Sciences ,Biomedical and clinical sciences ,Health sciences - Abstract
BackgroundMolecular tweezers (MTs) are broad-spectrum inhibitors of abnormal protein aggregation. A lead MT, called CLR01, has been demonstrated to inhibit the aggregation and toxicity of multiple amyloidogenic proteins in vitro and in vivo. Previously, we evaluated the effect of CLR01 in the 3 × Tg mouse model of Alzheimer's disease, which overexpresses mutant human presenilin 1, amyloid β-protein precursor, and tau and found that subcutaneous administration of the compound for 1 month led to a robust reduction of amyloid plaques, neurofibrillary tangles, and microgliosis. CLR01 also has been demonstrated to inhibit tau aggregation in vitro and tau seeding in cell culture, yet because in Alzheimer's disease (AD) and in the 3 × Tg model, tau hyperphosphorylation and aggregation are thought to be downstream of Aβ insults, the study in this model left open the question whether CLR01 affected tau in vivo directly or indirectly.MethodsTo determine if CLR01 could ameliorate tau pathology directly in vivo, we tested the compound similarly using the P301S-tau (line PS19) mouse model. Mice were administered 0.3 or 1.0 mg/kg per day CLR01 and tested for muscle strength and behavioral deficits, including anxiety- and disinhibition-like behavior. Their brains then were analyzed by immunohistochemical and biochemical assays for pathological forms of tau, neurodegeneration, and glial pathology.ResultsCLR01 treatment ameliorated muscle-strength deterioration, anxiety-, and disinhibition-like behavior. Improved phenotype was associated with decreased levels of pathologic tau forms, suggesting that CLR01 exerts a direct effect on tau in vivo. Limitations of the study included a relatively short treatment period of the mice at an age in which full pathology is not yet developed. In addition, high variability in this model lowered the statistical significance of the findings of some outcome measures.ConclusionsThe findings suggest that CLR01 is a particularly attractive candidate for the treatment of AD because it targets simultaneously the two major pathogenic proteins instigating and propagating the disease, amyloid β-protein (Aβ), and tau, respectively. In addition, our study suggests that CLR01 can be used for the treatment of other tauopathies in the absence of amyloid pathology.
- Published
- 2021